Regeneron Pharmaceuticals holds the cleaner structural position, with the lead spread across valuation and profitability. Edwards Lifesciences does not offset that deficit through any equally strong structural edge elsewhere. The market setup is currently leaning toward Edwards Lifesciences, which does not confirm the structural lead. That leaves a split case: the structural lead stays with Regeneron Pharmaceuticals, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.
The clearest separation starts in valuation, but profitability adds another real layer to the result. Regeneron Pharmaceuticals, Inc. leads by 21 points on the overall comparison score.
These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.
A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.
The clearest structural overlap shows up in revenue stability and operating margin level.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Score differences across key dimensions.
Left means cheaper relative valuation. Higher means stronger structure.
Regeneron Pharmaceuticals, Inc. and Edwards Lifesciences Corporation look relatively close on structure, but the price setup still leans toward Regeneron Pharmaceuticals, Inc..
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where EW and REGN each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The multiple-based pricing edge comes from a forward P/E that is 11.2 turns lower.
Edwards Lifesciences Corporation still carries lower volatility exposure — that difference is real enough to prevent the comparison from becoming one-sided.
The lead is built on both valuation and profitability, making it broader than a single-dimension result.
Break down the EW vs REGN comparison across all dimensions with the full interactive tool.
Explore how EW and REGN each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.